25,729 articles
Telikibart
Telikibart (GR1802, 泰利奇拜单抗) is Genrix Bio's fully human anti-IL-4Rα IgG1κ monoclonal antibody for atopic dermatitis, CRSwNP, urticaria, rhinitis, and asthma; Phase 3 in China, NDA accepted by NMPA in 2025.
Telisotuzumab vedotin
Telisotuzumab vedotin (Teliso-V, Emrelis, ABBV-399) is a c-Met-directed antibody-drug conjugate of telisotuzumab plus MMAE, FDA accelerated approval May 14, 2025 for previously treated high c-Met overexpressing nonsquamous NSCLC.
Telitacicept
Telitacicept (泰它西普, RC18, brand Tai'ai) is a RemeGen-developed TACI-Fc dual BLyS/APRIL inhibitor approved in China for SLE, RA, gMG, Sjögren's disease, and IgA nephropathy; phase 3 SLE trial showed SRI-4 response 67.1% vs 32.7%.
Telithromycin
Telithromycin (Ketek), the first ketolide antibiotic, derived from macrolides, treated community-acquired respiratory infections at 800 mg once daily. Withdrawn from the EU in 2019 and unavailable in the US after hepatotoxicity and myasthenia gravis warnings.
Teller Acuity Cards
Teller Acuity Cards (TAC) are a behavioral vision test measuring grating acuity in infants, toddlers, and other preverbal patients by preferential looking, introduced in 1986.
Telmisartan
Telmisartan (MICARDIS) is an angiotensin II receptor blocker approved in 1998 for hypertension and cardiovascular risk reduction, distinguished among ARBs by partial PPARγ agonism, high lipophilicity, and biliary elimination.
TELO2-related intellectual disability-neurodevelopmental disorder
TELO2-related intellectual disability-neurodevelopmental disorder, or You-Hoover-Fong syndrome, is an ultra-rare autosomal recessive TELO2 (16p13.3) disorder with severe developmental delay, microcephaly, movement disorder, and impaired balance.
Telogen effluvium
Telogen effluvium (TE) is a common, temporary, non-scarring diffuse hair shedding that begins two to three months after stressors such as illness, childbirth, surgery, or COVID-19, and usually resolves within six months.
Telotristat
Telotristat (Xermelo, telotristat ethyl/etiprate) is an oral tryptophan hydroxylase inhibitor approved in 2017 for carcinoid syndrome diarrhea in adults inadequately controlled by somatostatin analog therapy; 250 mg three times daily with food.
Telpegfilgrastim
Telpegfilgrastim (拓培非格司亭) is a long-acting PEGylated G-CSF developed by Xiamen Amoytop Biotech and approved in China in June 2023 to reduce febrile neutropenia in chemotherapy patients.
Temafloxacin
Temafloxacin (Omniflox, Abbott) was a fluoroquinolone antibiotic approved in the US in January 1992 and withdrawn worldwide in June 1992 after immune hemolytic anemia, renal failure, and hypoglycemia caused three deaths.
Temazepam
Temazepam (Restoril) is a Schedule IV benzodiazepine hypnotic, a minor metabolite of diazepam, used short-term for insomnia; 15 mg usual dose, ~10 h half-life, no active metabolites.
Temocillin
Temocillin is a semisynthetic 6-α-methoxy derivative of ticarcillin, a narrow-spectrum penicillin active against Enterobacterales including ESBL- and AmpC-producing strains; developed in the 1980s, abandoned, and revived as a carbapenem-sparing antibiotic.
TEMODELTA trial
TEMODELTA (NCT03557840) is a Belgian open-label, non-randomized pharmacokinetic trial of temocillin plasma protein binding and PK/PD in non-ICU patients with urinary, respiratory, or abdominal infections, sponsored by Paul M. Tulkens at UCLouvain.
Temoporfin
Temoporfin (mTHPC, Foscan) is a second-generation chlorin photosensitizer activated at 652 nm, EMA-authorized since 2001 for palliative PDT of advanced head and neck squamous cell carcinoma; FDA authorization was declined.
Temozolomide
Temozolomide (Temodal, Temodar) is an oral alkylating chemotherapy for malignant glioma, converted to MTIC to damage tumor DNA. Approved in 1999, it is standard with radiotherapy for newly diagnosed glioblastoma and treats anaplastic astrocytoma.
Temperature play
Temperature play, also called hot and cold play, is a consensual erotic or BDSM sensory practice using controlled warmth and coolness, such as ice, warm oil, or low-temperature wax, with burn and frostbite risk managed through negotiation and safewords.
TEMpEST trial
TEMpEST (Efficacy and Mechanism of Trientine in Patients with Hypertrophic Cardiomyopathy) is a UK phase 2, double-blind, placebo-controlled trial of trientine, a copper chelator, in HCM; 52 weeks, primary outcome LV mass index by CMR, results published 2026.
TEMPI syndrome
TEMPI syndrome, or telangiectasia-erythrocytosis-monoclonal gammopathy-perinephric fluid collections-intrapulmonary shunting syndrome, is an ultra-rare plasma cell disorder first named in 2011, treated with bortezomib and other plasma cell-directed therapy.
TEMPLAR study
The TEMPLAR study, for Telemonitoring of Blood Pressure in Local phARmacies, is an Italian registry assessing ambulatory blood pressure control in community pharmacies, led by Stefano Omboni.
Temple-Baraitser syndrome
Temple-Baraitser syndrome (TBS, OMIM 611816, ORPHA 420561) is a rare KCNH1 gain-of-function channelopathy with severe intellectual disability, epilepsy, and absent or hypoplastic thumb and great-toe nails; allelic to Zimmermann-Laband syndrome, unrelated to Temple syndrome.
Temporal artery biopsy
Temporal artery biopsy is a minor procedure removing a segment of the temporal artery under local anesthesia to confirm giant cell arteritis, the traditional gold-standard test.
Temporal bone
Temporal bone: paired lateral skull bone (os temporale) with squamous, tympanic, styloid, mastoid, and petrous parts; houses the ear, facial and vestibulocochlear nerves, carotid artery, and jugular vein.
Temporal interference stimulation
Temporal interference stimulation is a noninvasive brain stimulation technique, introduced by Nir Grossman and colleagues in 2017, that uses two high-frequency currents to reach deep brain regions without implanted electrodes.
Temporal lobe
Temporal lobe: one of the four cerebral lobes, below the lateral sulcus (Sylvian fissure). Handles hearing (Heschl gyri), language, emotion, and memory via the medial temporal lobe memory system; temporal lobe epilepsy is the most common focal epilepsy syndrome.
Temporal lobe epilepsy
Temporal lobe epilepsy (TLE), the most common focal epilepsy, involves seizures starting in the temporal lobes; mesial TLE with hippocampal sclerosis causes déjà vu auras and is often treated with surgery or laser ablation.
Temporary Dental Restoration
A temporary dental restoration is a prosthesis placed for days to months to seal a tooth between root canal sessions or while a permanent crown or bridge is made.
Temporomandibular joint
Temporomandibular joint (TMJ), the bilateral synovial jaw joint between the mandibular condyle and temporal bone with a fibrocartilage disc; unique to mammals, evolved from the cynodont dentary-squamosal articulation, and the site of temporomandibular disorders.
Temporomandibular joint dysfunction
Temporomandibular joint dysfunction (TMD): a group of more than 30 conditions causing jaw joint and chewing muscle pain, affecting 5–10% of the U.S. population, twice as common in women, treated mainly with conservative, reversible care.
Temtamy preaxial brachydactyly syndrome
Temtamy preaxial brachydactyly syndrome (TPBS, OMIM 605282) is a rare autosomal recessive CHSY1-related disorder with preaxial brachydactyly, hyperphalangism, hearing loss, dental anomalies, and developmental delay; about 18 cases reported.